The panel debates the various treatment options and comments on when they prefer each one.
Luspatercept Lessens RBC Transfusion Burden in MDS
September 7th 2023Results from the COMMANDS trial led the FDA to approve luspatercept for the treatment of anemia without prior erythropoiesis-stimulating agent use in adult patients with very low- to intermediate-risk MDS who may require regular red blood cell transfusions.
Read More
2 Clarke Drive
Cranbury, NJ 08512